TABLE 1.
Potential targets for myocardial infarction mRNA therapy.
| Reagent | Animal | Dose | Delivery method | Treatment result | Category | Reference |
|---|---|---|---|---|---|---|
| Human recombinant VEGF | Mice | 2.4 ng total | PLGA nanoparticle | LVFS: Control: ∼15% Treatment: ∼20% | Angiogenesis | Oduk et al. (2018) |
| Rat recombinant VEGF | Rat | 300 ng total | Alginate microsphere patch | LVFS: Control: ∼20% Treatment: ∼30% | Rodness et al. (2016) | |
| Basic FGF | Mice | 14 ng total | Intraperitoneal injection | LVFS: Control: ∼48% Treatment: ∼57% | Rao et al. (2020) | |
| Basic FGF | Rat | 5 µg total | Poly(NIPAAm-co-PAA-co-BA) hydorgel | LVFS: Control: ∼25% Treatment: ∼30% | Garbern et al. (2011) | |
| Acidic FGF | Mice | 500 ng total | Poly(ethylene argininylaspartate diglyceride) | LVEF: Control: ∼37% Treatment: ∼47% | Wang et al. (2017) | |
| Recombinant human HGF | Mice | 160 µg total | Intravenous injection | LVEDP: Control: ∼11 mmHg Treatment: ∼4 mmHg | Nakamura et al. (2000) | |
| CTGF human monoclonal antibody | Mice | 10 µg/g, 2 injections | Intraperitoneal injection | LVEF: Control: ∼16.5% Treatment: ∼27.1% | Fibrosis | Vainio et al. (2019) |
| Pharmaceutical inhibitor for TGF-β receptor (Activin receptor-like kinase 5) | Rat | 50 µg/g/day | Gavage | LVEF: Control: ∼43.7% Treatment: ∼51.8 | Tan et al. (2010) | |
| Recombinant agrin | Mice | 1 µg total | Intramyocardial injection | LVEF: Control: ∼41.9% Treatment: ∼55.0% | Cardiomyocyte proliferation | Bassat et al. (2017) |
| NOTCH ligand (Jagged-1 mimic) | Rat | N/A | Peptide hydrogel | LVEF: Control: ∼48% Treatment: ∼75% | Boopathy et al. (2015) | |
| Neuregulin-1, EGF-like domain | Mice | 2.5 µg total | Intraperitoneal injection | LVEF: Control: ∼22% Treatment: ∼32% | Bersell et al. (2009) |
LVFS, left ventricular fractional shortening; LVEF, left ventricular ejection fraction; LVEDP, left ventricular end-diastolic pressure.